Search

everythinglearnresearchcommunity

for

Search:↓

A user shared their two-month progress using dutasteride, minoxidil, ketoconazole shampoo, and tretinoin cream for hair loss, reporting no side effects and increased sex drive. Other users discussed their experiences with similar treatments, including finasteride and oral minoxidil, and debated the effectiveness of microneedling.

Hmi115, a prolactin receptor blocker, showed promise for hair growth, but results from Phase 2 trials have not been published. ABS-201, an AI-based analog, is expected to begin trials in December 2025, while commercialization of treatments like PP-405 is anticipated around 2027.

A 30-year-old is using topical minoxidil 6% and finasteride for hair loss, showing significant progress over five months. They also use dermastamping, nizoral shampoo, and had a hair and scalp treatment.

A person with Alopecia Areata on their beard is using CB-03-01 and oral minoxidil for treatment. Some users question the effectiveness of CB-03-01 for beard hair, suggesting that minoxidil alone may be responsible for any observed hair growth.

A 30-year-old considering a hair transplant has been using treatments like oral Minoxidil, Dutasteride, topical Minoxidil, copper peptide serum, red light laser therapy, microneedling, and vitamin therapy for hair loss. They are advised that a hair transplant is still an option, but maintaining current treatments is crucial to support the transplant and prevent further hair loss.

A 43-year-old male saw significant hair regrowth and increased density after three months using topical Minoxidil (5%), topical Finasteride (0.025%), and 0.75mm microneedling every two weeks, with no side effects. He plans to continue and may reduce Finasteride concentration if progress continues.

Hope Medicine's HMI-115 is expected to be released in 2027, with phase 3 trials currently recruiting. Concerns include the safety of targeting prolactin and the potential cost of the treatment.

A 24-year-old shares progress on hair regrowth after 3 months using 2.5mg oral minoxidil, 0.5mg dutasteride, and scalp injections of dutasteride, minoxidil, and vitamins every two weeks. They are uncertain if the improvement is due to actual regrowth or just longer hair.

The user stopped using finasteride and RU58841 and is considering CB-03-01 for androgenic alopecia but is concerned about the cost and effectiveness, especially at a lower dose than in clinical trials. They are also using minoxidil, micro-needling, and nizoral shampoo but are unsure about the correct application method for CB-03-01.

A 30-year-old man is considering quitting Finasteride due to sexual side effects, including reduced libido and difficulty reaching orgasm, despite its effectiveness in treating hair loss. He is exploring other factors like relationship issues and potential low testosterone, and is considering getting blood work done.

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. Users question effectiveness of HMI-115 and consider waiting longer for results.

A 26-year-old male is still experiencing hair loss after a year of using Dutasteride and is considering using CB0301 (Breezula) to block all androgens on his follicles. He is looking for a reliable source to purchase CB0301 and inquires about the availability of a premade solution.

A user shared their 3-month hair growth progress using 1mg oral finasteride, 5% topical minoxidil, and microneedling with a 1.5 mm dermaroller twice weekly. The user received positive feedback and expressed a desire for thicker hair in the future.

A 35-year-old male has been using finasteride inconsistently for two years and is hesitant about using minoxidil due to potential side effects. He is considering oral minoxidil and microneedling as alternatives and is unsure if dutasteride is too strong.

A 40-year-old male using microneedling, low-level laser therapy (LLT), and rosemary oil for hair regrowth. No finasteride or minoxidil is used.

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

The conversation is about a 40-year-old trying a homemade topical hair loss treatment combining finasteride and minoxidil, and considering microneedling after previous side effects from oral finasteride. They plan to provide updates on the results and any side effects.

The conversation discusses hair regrowth using microneedling, Minoxidil, and Finasteride over a three-month period. Specific treatments mentioned are microneedling, Minoxidil (Min), and Finasteride (Fin).

A 28-year-old has been using oral dutasteride 0.5 mg, topical minoxidil 5%, and Cafune shampoo for 104 days with positive results and is considering adding microneedling. No side effects from dutasteride have been reported.

A 31-year-old experienced significant hair regrowth using Minoxidil 5% topical twice daily and Finasteride 0.625mg daily, with additional microneedling. The user reported initial shedding, improved hair thickness, and no major side effects, impressing their dermatologist with the results.

A 31-year-old male shared his 4.5-month progress using finasteride, topical minoxidil, and dutasteride mesotherapy for hair loss, showing significant improvement in crown density and overall hair texture. He reported no side effects and plans to continue the treatment to assess further results.

The user reported hair regrowth progress using minoxidil and dermapen, considering adding finasteride. Others shared experiences with minoxidil, finasteride, and microneedling, recommending finasteride for long-term results but noting potential side effects.

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. HMI-115, a monoclonal antibody drug, is in phase 1 and 2 trials for different conditions, but its availability on the gray market is unlikely due to high production costs.

A user shared their 5-month progress using a topical treatment with finasteride, minoxidil, and retinoic acid, noting some hair growth but also shedding. Another user encouraged them, sharing their own experience of gradual improvement over 12 months and advising patience.

A user shared their successful hair loss treatment using RU58841, topical minoxidil, and microneedling, noting significant improvement over three months. They chose RU58841 over finasteride due to personal preference and reported no side effects, while others discussed their experiences with different treatments and supplements.

A 29-year-old male is using topical minoxidil and microneedling for hair regrowth and is considering adding finasteride. Users suggest adding finasteride for better results.

User started fin/min/niz at 23, switched to Dut at 24, and has been on treatments for 7 years. Despite occasional doubts, hair improved and user advises sticking with treatments.

The user reported hair thickening and new growth after using minoxidil and microneedling for over three months. They are considering finasteride but have not started it yet.

A 30-year-old male is considering switching from topical to oral minoxidil after two months of use on his temples, while also using dutasteride every other day. A user suggests oral minoxidil might be more effective but warns of potential side effects like fluid retention and lower blood pressure.

The user has been taking oral minoxidil and finasteride for 10 months with no hair growth but no further hair loss. They are considering adding rosemary oil and possibly returning to a topical solution.